In a report released on January 24, Conor McNamara from RBC Capital maintained a Buy rating on OmniAb (OABI – Research Report), with a price target of $7.00. The company’s shares closed yesterday at $6.19.
According to TipRanks, McNamara is an analyst with an average return of -10.0% and a 38.81% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Illumina, QuidelOrtho, and SOPHiA GENETICS.
OmniAb has an analyst consensus of Strong Buy, with a price target consensus of $9.17.
See Insiders’ Hot Stocks on TipRanks >>
OABI market cap is currently $705.6M and has a P/E ratio of -20.63.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OABI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OmniAb (OABI) Company Description:
Avista Public Acquisition Corp II is a blank check company.
Read More on OABI:
